Clinical Trial: Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07832799) titled 'Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose' on Sept. 16.

Brief Summary: The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two maridebart cafraglutide drug products in participants living with overweight or obesity.

Study Start Date: Oct. 12

Study Type: INTERVENTIONAL

Condition: Overweight Obesity

Intervention: DRUG: Maridebart Cafraglutide

Maridebart cafraglutide will be administered via SC injection.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Amgen

Disclaimer: Curated by HT Syndication....